Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05773196 · ClinicalTrials.gov registry record
Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study
A clinical trial of Huntington Disease and Huntington's Dementia, sponsored by Sanguine Biosciences.
- Recruiting
- Registry status
- 5
- Enrollment target
- 1
- Study location
NCT05773196: Recruiting study of Huntington Disease and Huntington's Dementia, sponsored by Sanguine Biosciences.
NCT05773196 is a study of Huntington Disease and Huntington's Dementia that is actively recruiting participants, run by Sanguine Biosciences. The registered enrollment target is 5 participants, below the 635-participant average among 35 other Huntington Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05773196, a study of Huntington Disease and Huntington's Dementia, is actively recruiting participants, sponsored by Sanguine Biosciences.
- RECRUITING
- Registry status
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
OBJECTIVES: The primary study objective is to collect blood from participants with Huntington's Disease in order to validate a CE marked Cytosine, Adenine, Guanine (CAG) assay for use in future studies for Huntington's Disease. The secondary study objective is to create a biorepository that can be used to identify disease associated biomarkers and potential targets with immune and multi-omics profiling. The disease sample collection and analysis will be the foundation for an extensive network of biospecimen access and linked datasets for future translational research.
Conditions Studied
Interventions
- OTHER Biospecimen Collection
Study Locations (1)
Massachusetts
- Sanguine Biosciences, Inc. - Woburn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-03-14 |
| Est. Completion | 2025-02-28 |
What NCT05773196 shows while recruiting
NCT05773196 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 635-participant average among 35 other Huntington Disease trials with a reported enrollment target (99% lower).
The record links to 4 conditions, with Huntington Disease appearing as the primary indexed condition, and to 1 intervention - of which Biospecimen Collection is the first listed.
NCT05773196 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05773196 about?
NCT05773196 is a clinical study titled "Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study". OBJECTIVES: The primary study objective is to collect blood from participants with Huntington's Disease in order to validate a CE marked Cytosine, Adenine, Guanine (CAG) assay for use in future studies for Huntington's Disease. The secondary study objective is to create a biorepository that can be...
What is the current status of trial NCT05773196?
This trial is currently recruiting. The enrollment target is 5 participants. The study started on 2023-03-14. Estimated completion is 2025-02-28.
What conditions does trial NCT05773196 study?
This clinical trial studies the following conditions: Huntington Disease, Huntington's Dementia, Huntington Disease, Late Onset, Huntington; Dementia (Etiology).
What interventions are being tested in trial NCT05773196?
The interventions under investigation include: Biospecimen Collection (OTHER).
Who is sponsoring clinical trial NCT05773196?
This trial is sponsored by Sanguine Biosciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05773196 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05773196's enrollment target sits among peer trials
5 36th of 35 the lowest of 35 other Huntington Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Huntington Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Longitudinal Endpoint Assessment of Disease Burden in HD
RECRUITING
-
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
RECRUITING
-
Extracellular Vesicles for HD
RECRUITING
-
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
RECRUITING · Phase 3
-
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI